Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$21.46
+0.3%
$21.04
$17.24
$28.56
$13.77B0.941.25 million shs598,453 shs
Genmab A/S stock logo
GNMSF
Genmab A/S
$214.95
+1.1%
$208.14
$170.00
$292.80
$14.20B0.9142 shs2 shs
Olympus Co. stock logo
OCPNY
Olympus
$18.00
-1.4%
$18.00
$16.80
$74.99
$23.15B0.7860,265 shs400 shs
Sysmex Corporation ADR stock logo
SSMXY
Sysmex
$16.78
-0.6%
$17.09
$14.38
$22.00
$10.56B1.1481,854 shs86,209 shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
+0.28%+4.58%-5.96%+9.99%-20.67%
Genmab A/S stock logo
GNMSF
Genmab A/S
0.00%+8.28%-4.17%+12.83%-17.99%
Olympus Co. stock logo
OCPNY
Olympus
0.00%0.00%0.00%0.00%0.00%
Sysmex Corporation ADR stock logo
SSMXY
Sysmex
-0.59%+1.21%-2.67%-11.73%+2.57%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
3.9728 of 5 stars
3.35.00.00.02.70.03.1
Genmab A/S stock logo
GNMSF
Genmab A/S
0.2345 of 5 stars
0.01.00.00.01.60.01.3
Olympus Co. stock logo
OCPNY
Olympus
N/AN/AN/AN/AN/AN/AN/AN/A
Sysmex Corporation ADR stock logo
SSMXY
Sysmex
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
2.64
Moderate Buy$37.8076.14% Upside
Genmab A/S stock logo
GNMSF
Genmab A/S
0.00
N/AN/AN/A
Olympus Co. stock logo
OCPNY
Olympus
0.00
N/AN/AN/A
Sysmex Corporation ADR stock logo
SSMXY
Sysmex
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest OCPNY, GMAB, GNMSF, and SSMXY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/8/2025
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$45.00 ➝ $46.00
(Data available from 7/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$3.12B4.41$1.52 per share14.11$8.04 per share2.67
Genmab A/S stock logo
GNMSF
Genmab A/S
$3.12B4.55$15.19 per share14.15$80.53 per share2.67
Olympus Co. stock logo
OCPNY
Olympus
$7.74B2.99$1.22 per share14.76$3.50 per share5.14
Sysmex Corporation ADR stock logo
SSMXY
Sysmex
$3.34B3.16$0.96 per share17.42$4.87 per share3.45
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$1.14B$1.7612.1912.066.5135.11%18.08%14.52%8/14/2025 (Estimated)
Genmab A/S stock logo
GNMSF
Genmab A/S
$1.14B$17.6312.19N/A35.11%19.23%15.44%8/7/2025 (Estimated)
Olympus Co. stock logo
OCPNY
Olympus
$1.03B$0.8221.9520.691.0713.80%24.30%9.30%N/A
Sysmex Corporation ADR stock logo
SSMXY
Sysmex
$354.21M$0.5629.9621.51N/A10.56%11.81%8.38%8/5/2025 (Estimated)

Latest OCPNY, GMAB, GNMSF, and SSMXY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q4 2025
Sysmex Corporation ADR stock logo
SSMXY
Sysmex
$0.1617$0.12-$0.0417$0.12$991.22 million$958.89 million
5/8/2025Q1 2025
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$0.23$0.31+$0.08$0.31$5.17 billion$715.00 million
5/8/2025Q1 2025
Genmab A/S stock logo
GNMSF
Genmab A/S
$1.88$3.05+$1.17$3.05$761.09 million$765.14 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
N/AN/AN/AN/AN/A
Genmab A/S stock logo
GNMSF
Genmab A/S
N/AN/AN/AN/AN/A
Olympus Co. stock logo
OCPNY
Olympus
$0.080.44%N/A9.76%N/A
Sysmex Corporation ADR stock logo
SSMXY
Sysmex
$0.160.95%N/A28.57%N/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
N/A
5.34
5.32
Genmab A/S stock logo
GNMSF
Genmab A/S
N/A
5.34
5.32
Olympus Co. stock logo
OCPNY
Olympus
0.59
1.99
1.48
Sysmex Corporation ADR stock logo
SSMXY
Sysmex
0.12
2.97
2.30

Institutional Ownership

CompanyInstitutional Ownership
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
7.07%
Genmab A/S stock logo
GNMSF
Genmab A/S
N/A
Olympus Co. stock logo
OCPNY
Olympus
0.03%
Sysmex Corporation ADR stock logo
SSMXY
Sysmex
N/A

Insider Ownership

CompanyInsider Ownership
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
1.54%
Genmab A/S stock logo
GNMSF
Genmab A/S
1.54%
Olympus Co. stock logo
OCPNY
Olympus
N/A
Sysmex Corporation ADR stock logo
SSMXY
Sysmex
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
2,682641.54 million631.66 millionOptionable
Genmab A/S stock logo
GNMSF
Genmab A/S
2,68266.07 million65.06 millionNot Optionable
Olympus Co. stock logo
OCPNY
Olympus
31,5571.29 billionN/ANot Optionable
Sysmex Corporation ADR stock logo
SSMXY
Sysmex
11,012629.48 millionN/ANot Optionable

Recent News About These Companies

Sysmex (OTCMKTS:SSMXY) Shares Gap Up - What's Next?
Sysmex (OTCMKTS:SSMXY) Shares Gap Up - Still a Buy?
MP: Mohan woos Sysmex, Panasonic Energy to set up facility in MP
Harding Loevner International Equity ADR Q3 2024 Report
NCLTY Nitori Holdings Co., Ltd.

New MarketBeat Followers Over Time

Media Sentiment Over Time

Genmab A/S stock logo

Genmab A/S NASDAQ:GMAB

$21.46 +0.06 (+0.28%)
Closing price 07/14/2025 04:00 PM Eastern
Extended Trading
$21.59 +0.13 (+0.61%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Genmab A/S stock logo

Genmab A/S OTCMKTS:GNMSF

$214.95 +2.40 (+1.13%)
As of 07/11/2025 11:55 AM Eastern

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Olympus stock logo

Olympus OTCMKTS:OCPNY

$18.00 -0.25 (-1.37%)
As of 01/31/2023

Olympus Corp. engages in the manufacture and sale of precision machineries and instruments. It operates through the following segments: Medical, Scientific Solutions, Imaging, and Others. The Medical segment covers digestive, surgical, and ultrasonic endoscopy as well as endoscopic treatment tools. The Scientific Solutions segment manufactures and sells biological and industrial microscopes, industrial endoscopes, and non-destructive testing equipment. The Imaging segment deals with digital cameras and recording devices. The Others segment includes biomaterial manufacturing and sales business. The company was founded by Takeshi Yamashita on October 12, 1919 and is headquartered in Tokyo, Japan.

Sysmex stock logo

Sysmex OTCMKTS:SSMXY

$16.78 -0.10 (-0.59%)
As of 07/14/2025 03:58 PM Eastern

Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan. It offers three-part and five-part white blood cell differentiation instruments for use in hematology; and transport systems for high-volume testing in labs. The company also provides automated urine particle analyzers; automated blood coagulation analyzers; automated immunochemistry systems, which perform assays on minute sample quantities, as well as reagents to test for infectious disease and tumor markers; and flow cytometers to perform analysis in diagnosing leukemia, malignant lymphoma, and HIV/AIDS. In addition, it offers cancer lymph node metastasis testing systems to detect information to help in diagnosing lymph node metastasis; and lab assay services. Further, the company is involved in the development and sale of software for diagnostic information systems; provision of facility management, office, welfare, and genetic analysis services; development, operation, and maintenance of IT solutions, platforms, and applications related to digital medicine; marketing, development, design, manufacture, sale, and after-sales service related to medical robots; and distribution and after sales support of medical devices and reagents for biotechnology, medical technology, and molecular cell analysis. Additionally, it researches, develops, manufactures, and sells regenerative medicine products; develops, manufactures, and sells biodevices; develops, maintains, and sells computer software; and offers blood DNA testing service. The company serves national and other public hospitals, private hospitals, universities, research institutes, other medical institutions, etc. It also exports its products to approximately 190 countries. The company was formerly known as TOA Medical Electronics Co., Ltd. and changed its name to Sysmex Corporation in October 1998. Sysmex Corporation was founded in 1968 and is headquartered in Kobe, Japan.